News & Resources
Current and relevant information for our customers.
Upcoming Events
HCP / May 22-24, 2023
Connect with us in Indianapolis at the Spring Hospital Pharmacy Conference.
Set up a time to meet
ASCO Scientific Program / June 2-6, 2023
Come see us in Chicago at the American Society of Clinical Oncology Scientific Program.
Set up a time to meet
ASHP Summer Meeting / June 10-14, 2023
Join us in Baltimore at the American Society of Health-System Pharmacists Summer Meeting.
Set up a time to meet
ATOPP / July 13-15, 2023
Connect with us in New Orleans at the Advanced Topics for Oncology Pharmacy Professionals show.
Set up a time to meet
RNS / August 2-5, 2023
Join us at the Rheumatology Nurses Society show.
Set up a time to meet
AWIR / August 10-13, 2023
Come see us in Orlando at the Association of Women in Rheumatology show.
Set up a time to meet
NPPA / August 15-17, 2023
Connect with us in Las Vegas at the National Pharmacy Purchasing Association show.
Set up a time to meet
Resources
Biosimilars: Realizing the potential in the U.S.
Download
At the forefront of health care innovation
Fresenius Kabi develops reliable, high-quality biosimilars for autoimmune diseases and oncology. Learn how we as a global health care company are at the forefront of health care innovation and patient care.
Providing affordable medicines
Fresenius Kabi: caring for life
What biosimilars mean to me
Fresenius Kabi is a member of the Biosimilars Council
The Biosimilars Council works to ensure a positive regulatory, reimbursement, political and policy environment for biosimilar products. The council educates the public and patients about the safety and effectiveness of biosimilars, focusing on access, the regulatory environment, reimbursement and legal affairs.
Useful information and resources from the Biosimilars Council:
Fresenius Kabi is a member of the Biosimilars Forum
The Biosimilars Forum is a nonprofit organization whose mission is to advance biosimilars in the United States with the intent of expanding access and availability of biological medicines and improving health care. The founding members of the Biosimilars Forum represent the majority of companies with the most significant U.S. biosimilars development portfolios.
News
May 16, 2023
CMS grants Fresenius Kabi permanent, product-specific Q-Code for Stimufend® (pegfilgrastim-fpgk)
February 16, 2023
Stimufend® (pegfilgrastim-fpgk) Now Available in the United States
January 27, 2023
Biosimilar Adalimumab-aacf Gains FDA Approval, Marks Growing Interest in Biosimilar Development
December 14, 2022
Fresenius Kabi receives U.S. FDA approval for biosimilar Idacio® (adalimumab-aacf)
September 6, 2022
Fresenius Kabi receives U.S. FDA approval for biosimilar Stimufend® (pegfilgrastim-fpgk)
June 2022
Fresenius Kabi joins the Biosimilars Forum
November 2, 2021
Fresenius Kabi USA Executive Discusses Pegfilgrastim Biosimilar Prospects
September 7, 2021
Fresenius Kabi provides update on clinical trials for biosimilar candidate Tocilizumab
September 7, 2021
Sign up: INS Learning Center – Supportive Care Therapies: Complexities Made Simple
July 13, 2021
Meeting | Hearings | United States Senate Committee on the Judiciary
June 21, 2021
Fresenius Kabi Receives Premier Supplier Legacy Award
May 24, 2021
New White Paper Identifies Patent Thickets as Barrier to US Biosimilars Market and Domestic Manufacturing
April 19, 2021
Managing chemotherapy-induced neutropenia in 2021
To follow all the latest from Fresenius Kabi and our events, please use any of the links below.